Severe ifosfamide-induced neurotoxicity: a case report

被引:0
|
作者
Sara Ramos Linares
Joaquín Breña Atienza
Matilde Cháfer Rudilla
Pablo Ríos Rull
Ana Cabello Rodríguez
Javier Merino Alonso
机构
[1] Hospital Universitario Nuestra Señora de Candelaria,Pharmacy Department
[2] Hospital Universitario Nuestra Señora de Candelaria,Hematology Department
来源
Pharmacy World & Science | 2010年 / 32卷
关键词
Ifosfamide; Neurotoxicity; Risk factors; Treatment;
D O I
暂无
中图分类号
学科分类号
摘要
Introduction Ifosfamide is an alkylating agent used in the treatment of several neoplasias. Ifosfamide metabolites accumulation can produce neurotoxicity, which sometimes manifests as a severe clinical picture. Case description We describe the case of a male with a mixed cellularity subtype classical Hodgkin’s lymphoma, treated with ifosfamide after other chemotherapy drugs failure. After the first Ifosfamide cycle, the patient showed severe neurological toxicity that resolved 3 weeks later with supportive therapy. Discussion Among the risk factors described in the literature, our patient had previously received cysplatin chemotherapy, had low albumin serum levels, and had received ifosfamide as a rapid intravenous infusion. The management of the neurotoxicity is symptomatic although some drugs, like methylene blue and albumin, have also been used. Conclusion This case highlights that clinicians should be aware of the possibility of severe neurological toxicity after the administration of ifosfamide and may control the risk factors associated.
引用
收藏
页码:109 / 111
页数:2
相关论文
共 50 条
  • [1] Severe ifosfamide-induced neurotoxicity: a case report
    Ramos Linares, Sara
    Brena Atienza, Joaquin
    Chafer Rudilla, Matilde
    Rios Rull, Pablo
    Cabello Rodriguez, Ana
    Merino Alonso, Javier
    PHARMACY WORLD & SCIENCE, 2010, 32 (02): : 109 - 111
  • [2] IFOSFAMIDE-INDUCED NEUROTOXICITY - A CASE-REPORT AND REVIEW OF THE LITERATURE
    MILLER, LJ
    EATON, VE
    ANNALS OF PHARMACOTHERAPY, 1992, 26 (02) : 183 - 187
  • [3] IFOSFAMIDE-INDUCED NEUROTOXICITY
    CURTIN, JP
    KOONINGS, PP
    GUTIERREZ, M
    SCHLAERTH, JB
    MORROW, CP
    GYNECOLOGIC ONCOLOGY, 1991, 42 (03) : 193 - 196
  • [4] Suspected ifosfamide-induced neurotoxicity
    McVay, JI
    Wood, AM
    PHARMACOTHERAPY, 1999, 19 (12): : 1450 - 1455
  • [5] HALLUCINATIONS AND IFOSFAMIDE-INDUCED NEUROTOXICITY
    DIMAGGIO, JR
    BROWN, R
    BAILE, WF
    SCHAPIRA, D
    CANCER, 1994, 73 (05) : 1509 - 1514
  • [6] Possible contribution of aprepitant to ifosfamide-induced neurotoxicity
    Jarkowski, Anthony, III
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (23) : 2229 - 2231
  • [7] Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review
    Fatemeh Vazirian
    Sara Samadi
    Hossein Rahimi
    Masoomeh Sadeghi
    Amir Hooshang Mohammadpour
    Cancer Chemotherapy and Pharmacology, 2022, 90 : 1 - 6
  • [8] Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review
    Vazirian, Fatemeh
    Samadi, Sara
    Rahimi, Hossein
    Sadeghi, Masoomeh
    Mohammadpour, Amir Hooshang
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 90 (01) : 1 - 6
  • [9] Ifosfamide-induced acute kidney injury in a patient with leiomyosarcoma: A case report
    Boskabadi, Javad
    Yousefi-Mazhin, Ehsan
    Salehifar, Ebrahim
    CANCER REPORTS, 2022, 5 (10)
  • [10] CONCENTRATING CAPACITY IN IFOSFAMIDE-INDUCED SEVERE RENAL DYSFUNCTION
    ROSSI, R
    GODDE, A
    KLEINEBRAND, A
    RATH, B
    JURGENS, H
    RENAL FAILURE, 1995, 17 (05) : 551 - 557